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The microphthalmia-associated transcription factor is
implicated in melanocyte development and in the reg-
ulation of melanogenesis. Microphthalmia-associated
transcription factor is thought to bind to the M-box
promoter elements of tyrosinase, tyrosinase-related
protein-1 and dopachrome tautomerase/tyrosinase-
related protein-2 and transactivate these genes, resulting
in increased pigmentation. Using a luciferase reporter
construct driven by the microphthalmia-associated
transcription factor promoter, we identi¢ed agents that
modulate microphthalmia-associated transcription fac-
tor promoter activity. Changes in endogenous micro-
phthalmia-associated transcription factor expression
levels upon treatment with these agents were con¢rmed
using northern and western blots, and their pigmentary
modulating activities were demonstrated. Ultraviolet B
irradiation and traditional Chinese medicine-1, a natur-
al extract used in traditional Chinese medicine, upregu-
lated microphthalmia-associated transcription factor
gene expression and enhanced tyrosinase activity
in vitro. Dihydrolipoic acid, lipoic acid, and resveratrol
reduced microphthalmia-associated transcription factor
and tyrosinase promoter activities. These agents also in-
hibited the forskolin- and ultraviolet B-stimulated pro-
moter activities of these genes and signi¢cantly reduced
tyrosinase activity in melanocyte cultures, resulting in
depigmentation. Overexpressed microphthalmia-asso-
ciated transcription factor was capable of rescuing the
repressive e¡ects of these compounds on the cotrans-
fected tyrosinase promoter. Dark-skinned Yucatan
swine treated with these agents showed visible skin
lightening, which was con¢rmed histologically, whereas
ultraviolet B-induced tanning of light-skinned swine
was inhibited using these agents. Our ¢ndings suggest
that modulation of microphthalmia-associated tran-
scription factor expression can alter skin pigmentation
and further con¢rm the central role of microphthal-
mia-associated transcription factor in melanogenesis.
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S
kin pigmentation, resulting from the production and
distribution of melanin in the epidermis, is the major
physiologic defense against solar irradiation. In mam-
mals, melanogenesis is stimulated by ultraviolet (UV)B
irradiation, a-melanocyte-stimulating hormone (a-MSH),
and cyclic adenosine monophosphate (cAMP)-elevating agents
(e.g., forskolin, isobutylmethylxanthine) (Abdel-Malek et al,
1987). Melanin is synthesized in epidermal melanocytes,
and then transferred into epidermal keratinocytes via the melano-
cytes’dendrites (Le Douarin, 1982). Three melanocyte-speci¢c en-
zymes, tyrosinase, tyrosinase-related proteins-1 (TRP-1/Tyrp1)
and dopachrome tautomerase (DCT, also known as tyrosinase re-
lated protein-2,TRP-2) are involved in the enzymatic conversion
of tyrosine to melanin (Korner and Pawelek, 1982; Barber et al,
1984; Hearing and Jimenez, 1987; Prota, 1988; Jimenez-Cervantes
et al, 1994; Yokoyama et al, 1994). The promoter sequences of tyr-
osinase, Tyrp1, and DCT share a highly conserved motif termed
the M-box, which contributes to their melanocyte-speci¢c
expression (Yasumoto et al, 1997; Aksan and Goding, 1998). The
microphthalmia-associated transcription factor (MITF), a basic
helix^loop^helix leucine zipper transcription factor, is thought
to bind to the M-box and transactivates the tyrosinase, Tyrp1,
and DCT promoters (Hemesath et al, 1994; Yasumoto et al, 1997;
Aksan and Goding, 1998). MITF is involved in melanocyte devel-
opment and survival (Moore, 1995; Fisher, 2000), and overexpres-
sion of MITF in NIH/3T3 ¢broblasts could induce dendricity
and tyrosinase and Tyrp1 expression (Tachibana et al, 1996).
Homozygous mutations at the mouse microphthalmia (Mi) locus
lead to a complete loss of pigmentation due to melanocyte loss
(Silvers, 1979; Tachibana et al, 1994). Mutations in the human
homolog of the mouse Mi gene result in abnormal pigmentation
and deafness, as observed in Waardenburg syndrome type IIA
(Tachibana et al, 1994; Tassabehji et al, 1994, 1995; Nobukuni et al,
1996; Bondurand et al, 2000). The MITF gene contains multiple
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promoters, which give rise to unique 50 exons, subsequently
spliced on to a common downstream coding region (Udono
et al, 2000). One of these alternative promoters is melanocyte spe-
ci¢c (Fuse et al, 1996) and contains a cAMP response element
(CRE) consensus motif. The melanocyte-speci¢c MITF promo-
ter CRE is believed to mediate cAMP-induced melanogenesis in
response to MSH stimulation (Wong and Pawelek, 1975; Halaban
et al, 1984; Gordon et al, 1989; Takahashi and Parsons, 1990; Hunt
et al, 1994; Fuse et al, 1996; Bertolotto et al, 1998; Price et al, 1998b).
The signi¢cance of MITF as a master regulator of melanogen-
esis led us to search for agents that modulate MITF expression,
and therefore might a¡ect skin pigmentation. Here we show
that UVB irradiation and the natural extract traditional Chinese
medicine-1 (TCM-1) activate the melanocyte-speci¢c MITF pro-
moter, whereas dihydrolipoic acid (DHLA), lipoic acid (LA),
and resveratrol (trans-3,40,5-trihydroxystibene) reduce MITF
expression, and induce skin lightening in vivo.
MATERIALS AND METHODS
Reagents Chemicals were from Sigma (St Louis, MO). Pycnogenol was
from Cogniz Corporation (Cincinnati, OH) and a concentrated green tea
polyphenols extract was from Lipton (Grand Rapids, MN). TCM-1, an
aqueous extract of the plant Astragulus membraneus Bunge. Ex Maxim was
kindly provided by Dr Zhi Sheng He (Shanghai Institute of Material
Medica, Chinese Academy of Science, Shanghai, China).
Cell cultures Dulbecco’s modi¢ed Eagle’s medium, fetal bovine serum,
trypsin, penicillin, and streptomycin were from Life Technologies
(Rockville, MD). Primary normal human epidermal melanocytes
(neonatal, NHEM) were purchased from Cascade Biologics, Inc.
(Portland, OR) and were maintained according to the manufacturer’s
instructions. Human HaCaT keratinocytes (kind gift of Dr N.E. Fusenig,
Heidelberg, Germany) were maintained as described (Boukamp et al, 1988).
B16 murine melanoma cells were from the American Type Culture
Collection (Manassas, VA) and were maintained according to the
manufacturer’s instructions. The murine melanocyte line melan-a (kind
gift of Dr D. Bennett, St George’s Hospital Medical School, London,
U.K.) was maintained according to Bennett et al (1987). Viability assays
were performed using alamarBlueTM (Acumed International, West Lake,
OH) following manufacturer’s instructions. UVB irradiation (typically, 30
mJ per cm2 for melanocytes and 18.8 mJ per cm2 for keratinocytes) was
performed with a UVB FS light source (Spectronics Corp.Westbury, NY,
Ble-1T158 light bulb) in an exposure chamber, with plate covers removed
and phosphate-bu¡ered saline (PBS) present in the wells. UVB intensity
was measured with a UVX radiometer (UVP Inc., San Gabriel, CA).
After irradiation, PBS was immediately replaced with maintenance
medium. All studies were repeated at least three times.
Reporter and expression constructs The human MITF promoter
(^387 to þ 97 bp, in pGL2.hMIP) (Fuse et al, 1996) was cloned upstream
of the ¢re£y luciferase gene as described (Price et al, 1998a). The human
tyrosinase promoter (^300 to þ 80 bp) luciferase reporter construct is
described in (Price et al, 1998a). The human Tyrp1 promoter (^344 to
þ 114 bp) luciferase construct (pGL3.HTyrp1) (Yavuzer and Goding, 1994)
was kindly provided by Dr C.R. Goding (Marie Curie Research Institute,
The Chart, Oxted, U.K.). The dominant negative MITF mutant construct
mutCRE-MITF (pGL2.hMiPmutCRE) is described by Price et al (1998a).
For the rescue experiments, MITF was expressed from the elongation
factor 1a promoter (Mizushima and Nagata, 1990) using pEBB MITF as
described byWu et al (2000). All studies were repeated at least three times.
Reporter assays Reporter and expression constructs were transfected
into HaCaT, NHEM, B16, or melan-a cells using FugeneTM 6 according
to the manufacturer’s instructions (Roche Molecular Biochemicals,
Indianapolis, IN). Forty-eight hours post-transfection, cells were treated
with test compounds for 7 h or as otherwise indicated. Cells were
harvested using the passive lysis bu¡er and assayed using the Dual
Luciferase assay according to manufacturer’s instructions (Promega,
Madison, WI). Luciferase values were normalized to constitutive Renilla
(sea pansy) luciferase produced from cotransfected pRL-Null plasmid
(Promega).
cAMP (low pH) immunoassay cAMP concentration was analyzed
using a cAMP (low pH) kit from R&D systems, Inc. (Minneapolis, MN).
In brief, B16 cells (7104) were lyzed in 0.1 M of HCl to inhibit
phosphodiesterase activity. Supernatants were collected, neutralized, and
diluted. Following neutralization and dilution, a ¢xed amount of cAMP
conjugate (alkaline phosphatase-labeled cAMP) was added to compete
with cAMP present in the cell lysates for sites on a rabbit polyclonal
antibody immobilized on a 96 well plate. After a wash to remove excess
conjugated and unbound cell lysate cAMP, a substrate solution was added
to the wells to determine the bound enzyme activity. The color
development was stopped and the absorbance was read at 405 nm.
The intensity of the color was inversely proportional to the concentration
of cAMP in the cell lysates. All studies were repeated at least three times.
RNA isolation and northern blot analysis Total RNA was isolated
using RNA STAT-60TM (TEL-TEST, Inc., Friendswood, TX) according
to manufacturer’s instructions. Twenty micrograms of total RNA were
separated on a 1% agarose gel, and transferred on to Gene Screen plus
membrane (Du Pont-NEN, Boston, MA). Hybridization was performed
in ExpressHybTM Hybridization Solution (Clontech, Palo Alto, CA)
according to the manufacturer’s instructions, using a human MITF cDNA
fragment (base pairs 58^1432) as a probe.
Protein extraction and western blot analysis Western blot analysis
was performed on B16 cell extracts as previously described (Sharlow et al,
2000). Brie£y, B16 cells were lyzed in RIPA bu¡er containing 1% nonidet-
P40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate,
CompleteTM protease inhibitors (Boehringer Mannheim, Indianapolis,
IN) and phosphatase inhibitors (1 mM sodium vanadate and 20 mM
sodium £uoride) in PBS. RIPA lysates (20 mg per lane) were
electrophoresed in 10% sodium dodecyl sulfate^polyacrylamide gel
electrophoresis gels and proteins were analyzed by enhanced chemi-
luminescence western blotting (Amersham, Arlington Heights, IL).
Antibodies used are monoclonal antibodies against Mi (Hemesath et al,
1998), and polyclonal antibody against tyrosinase (aPEP-7 kind gift of Dr
V. Hearing, National Cancer Institute, NIH, Bethesda, MD) and against a-
tubulin (loading control).
Tyrosinase activity analysis and 3,4-dihydroxyphenylalanine
(DOPA) staining For total tyrosinase activity analysis, control and
treated cells were trypsinized with 0.25% trypsin and cells (7104) were
then lyzed in 1% Triton-X 100 in 0.1 M Na phosphate bu¡er (pH 6.8) for
approximately 20 min. Lysates (100 ml) were incubated with 100 ml of
DOPA, 3 mg per ml in 0.1 M Na phosphate bu¡er (pH 6.8), at 371C, for 3
h. Tyrosinase activity was determined by measuring absorbance at 490 nm
(UV Max Kinetic Microplate Reader, Molecular Device, Sunnyvale, CA).
To measure inhibition of tyrosinase enzymatic activity only, aliquots of
lysates from untreated cells were incubated with both DOPA and test
compounds at 371C for 3 h and then analyzed for tyrosinase activity as
described above. For in-situ DOPA staining, cells were ¢xed in 1.85%
formaldehyde and 2 mg glutaraldehyde per ml in PBS for 5 min, washed
with PBS, and incubated with 0.1% DOPA in 0.1 M sodium phosphate
bu¡er for 4^5 h at 371C following by PBS washes. Images of the stained
cells were taken using a Leitz-Diaplan microscope (Nurnberg, Germany)
and a Polaroid 35 mm camera for Digital Palette (Cambridge, MA).
Images were analyzed using Image Pro Plus 4.0 software (Media
Cybernetics, Silver Spring, MD). All studies were repeated at least three
times.
Swine Yucatan swine (Charles River, Portland, ME) were housed in
appropriately sized cages in an environmentally controlled room with a 12
h light/12 h dark photoperiod and supplied with food and water ad
libitum. Animal care and use complied with the criteria described in the
guide published by the U.S. National Institutes of Health, 1996. Twenty
microliters of test material or vehicle (ethanol/propylene glycol, 70 : 30 v/v)
was applied topically, twice a day, 5 d per wk, for 8 wk, on the dorsum of
swine. Treatments of individual swine were always arranged in a head to
tail order on one side, and in a tail to head order on the other side of the
animal.Visual observations of lightening were made weekly. Biopsies were
taken at the end of the study using standard techniques. Swine experiments
were repeated with at least three individual swine. A mean erythema dose
of UVB was determined by placing a plastic template with 11 inch2
cutouts on the dorsum of the swine. Using a UVB lamp (Model UVM-
57, 302 nm lamp, UVP Inc., Upland, CA) placed on the template, sites
were exposed to UVB with increasing time points, every other day for 5
d. Unexposed sites were covered with the same material as the template.
One mean erythema dose was established as the dose that produces the
least amount of visible erythema. Swine were exposed to one mean
erythema dose, once per day, on three alternate days (Monday,Wednesday,
Friday). Test compounds were applied once daily, for 2 wk, immediately
after each UVB exposure, and on non-UVB exposure days. To prevent a
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possible sunscreen e¡ect, the treated sites were cleaned with water and
allowed to dry before each UVB exposure. Visual observations of the
tanning response were made after 2 wk, and biopsies were taken at that
time for histologic analysis. All swine studies presented here had no visual
irritation, and histologic analyses revealed no markers of irritation or other
pathologic signs.
Histology Sections from swine biopsies were stained with Fontana^
Mason (F&M) according to Sheehan and Hrapchak (1980). F&M detects
silver nitrate reducing molecules, which in skin identi¢es primarily
melanin. At least two biopsies per treatment, three sections per biopsy
were processed for each swine.
RESULTS
UVB and TCM-1 induce MITF promoter-luciferase
activity To evaluate the e¡ects of various agents on MITF
promoter activity, murine B16 melanoma cells, murine melan-a
melanocytes, and human HaCaT keratinocytes were transiently
transfected with the human MITF promoter-luciferase
construct. Validation of the system with forskolin, a known
cAMP elevating agent, revealed a concentration- and time-
dependent induction of MITF promoter transcription in
melanocytes, as previously described (Price et al, 1998b), but not
in keratinocytes (Fig 1a). Forskolin (100 mM) signi¢cantly induced
MITF promoter activity (91.0718% in B16 cells and 92.0þ 0.5%
in melan-a) compared with untreated controls (Fig 1a). a-MSH,
a known natural inducer of melanogenesis, also stimulated MITF
promoter activity in this system, but to a lower level (not shown)
as expected (Price et al, 1998b). Therefore, forskolin was used as a
positive control in this study. To understand better the molecular
mechanism of UVB-induced pigmentation, we examined the
e¡ect of UVB irradiation on MITF promoter activity. UVB
irradiation resulted in an increase in MITF promoter activity,
which was slightly lower than that induced by forskolin
(67.4728.6% in B16 cells and 62.2726.2% in melan-a) (Fig 1a).
The regulation of the MITF promoter via UVB irradiation was
found to be time dependent (Fig 1b). The maximal response to
UVB was observed at 7^8 h, whereas forskolin is known to
exert maximal e¡ect at 3^4 h post-treatment (Price et al, 1998b).
Concentration-dependent upregulation of the MITF promoter
activity was documented at lower dose exposures (Fig 1c) as
higher UVB exposure resulted in increased cytotoxicity.
Combination of UVB and forskolin showed an additive
response, suggesting that forskolin and UVB may not share
identical induction pathways (Fig 1a). These data indicate a
strong correlation between MITF promoter activation and
UVB-induced pigmentation. MITF promoter activity was not
detectable in HaCaT keratinocytes, when stimulated by either
forskolin or UVB radiation (Fig 1a), further indicating that the
stimulation of MITF promoter by forskolin and UVB is a
melanocyte-speci¢c event.
Interestingly, the natural extract TCM-1 induced MITF
promoter activation in a concentration-dependent manner. At
0.05 mg per ml,TCM-1 treatment resulted in a stimulation level
similar to that of 100 mM of forskolin (Fig 1d). The combined
e¡ect of TCM-1 and forskolin was found to be greater than that
of each treatment alone (Fig 1d), suggesting the possibility of
di¡erent induction mechanisms byTCM-1 and forskolin.
Figure1. Modulation of MITF promoter activity. HaCaT, B16, and melan-a cells, transfected with the MITF promoter-luciferase construct
(pGL2.hMIP) were treated, at 48 h after transfection, for 7 h with (a) forskolin (100 mM), UVB (30 mJ per cm2) and the combination of forskolin and
UVB. (b) Transfected B16 cells were treated with 30 mJ per cm2 for the times indicated. (c) Transfected B16 cells were treated with increasing doses of
UVB for 7 h. (d) Transfected B16 cells were treated with increasing concentrations of TCM-1 and combination of TCM-1 (0.1 mg per ml) and forskolin
(100 mM) as indicated. Measured luciferase activity is expressed as percent change of MITF promoter activity relative to untreated control (mean7SEM).
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Inhibition of MITF promoter-luciferase activity by DHLA,
LA, and resveratrol As anti-oxidants are known to a¡ect
pigment production (Hamanaka et al, 1990; Darr et al, 1996; Lee
and Youn, 1998; Firkle et al, 2000), we tested their possible
e¡ect on MITF promoter activity. Evaluation of a battery of
anti-oxidants revealed that only DHLA, LA, and resveratrol
could inhibit MITF promoter-luciferase activity. As shown in
Fig 2(a), these e¡ects were concentration dependent, with a
strong inhibitory activity at 400 mM for both DHLA and LA,
and 30 mg per ml for resveratrol. To assure that the observed
inhibition was not due to cytotoxicity, these compounds were
tested for their e¡ects on cell viability. No detectable changes in
cell viability were observed up to 600 mM concentrations of
DHLA and LA. In contrast, resveratrol inhibited MITF
promoter activity at a narrower range. At 10 mg per ml no
inhibitory activity was detected but at concentrations higher
than 30 mg per ml, resveratrol had a cytotoxic e¡ect. All other
anti-oxidants tested (e.g., ascorbic acid, ca¡eic acid, glutathione,
pycnogenol, and concentrated green tea polyphenols, not
shown), did not induce a signi¢cant inhibitory e¡ect in the
MITF promoter-luciferase assay.
DHLA, LA, and resveratrol inhibit forskolin and UVB-
induced MITF promoter activity The induction of MITF
promoter-luciferase activity by UVB irradiation (Fig 1a)
suggests that UVB-induced skin pigmentation could be
mediated via the activation of MITF gene expression. As anti-
oxidants can provide photoprotection (Hamanaka et al, 1990;
Darr et al, 1996; Lee and Youn, 1998; Firkle et al, 2000), we
examined the e¡ects of LA, DHLA, and resveratrol on UVB
and forskolin-induced MITF promoter activity. B16 cells
transfected with the MITF reporter construct were treated with
these agents in combination with either forskolin or UVB
irradiation. DHLA, LA, and resveratrol inhibited forskolin-
induced MITF promoter-luciferase activity (Fig 2b) and UVB-
induced MITF promoter-luciferase activity (Fig 2c) in a
concentration-dependent manner. DHLA was found to be less
potent in inhibiting UVB-induced MITF stimulation, compared
with its inhibition of forskolin-induced MITF activity, further
suggesting that UVB and forskolin do not share identical
induction pathways. Similar results were obtained using LA and
resveratrol (not shown).
The inhibition of either basal or forskolin-induced MITF
promoter activity by DHLA did not involve a change in cAMP
concentration in the treated melanocytes. As shown in Fig 2(d),
cAMP concentration increased only following treatment with
forskolin or a cell permeable cAMP. This increase of cAMP was
not inhibited by DHLA. Similarly, TCM-1 treatment had no
e¡ect on cAMP concentration, whereas MITF promoter activity
was strongly stimulated. Interestingly, a MITF promoter mutated
at the CRE lost almost completely its activity in B16 cells and
responded minimally to forskolin, TCM-1, or DHLA treatment
Figure 2. DHLA, LA, and resveratrol inhibit forskolin and UVB-induced MITF promoter activity. B16 cells transfected with the MITF promo-
ter-luciferase construct (pGL2.hMIP) were treated 48 h after transfection, with (a) Increasing concentrations of DHLA, LA, and resveratrol. (b) Forskolin
alone (100 mM), or in combination with DHLA (300 and 400 mM), LA (400 mM), or resveratrol (20 and 30 mg per ml); (c) UVB alone (30 mJ per cm2), or in
combination with DHLA (200 and 400 mM). Measured luciferase activity is expressed as percent increase of MITF promoter activity relative to untreated
control (mean7SEM). (d) B16 cells were treated with TCM-1, DHLA, forskolin, and cell permeable 8-bromo-cAMP at the concentrations indicated for 7
h. Measured cellular cAMP is expressed as percent increase of cAMP concentration relative to untreated control (mean7SEM).
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Figure 3. DHLA inhibits tyrosinase and TRP-1 promoter activities via the inhibition of MITF promoter. (a) DHLA inhibits MITF, tyrosinase,
and TRP-1 promoter activities. Melan-a and B16 cells were transfected with MITF, tyrosinase, or TRP-1 promoter luciferase reporter constructs. At 48 h
after transfection, cells were treated with forskolin (100 mM), DHLA (400 mM), or their combination for 7 h. Measured luciferase activity is expressed as
percent of the basal luciferase activity relative to untreated control (mean7SEM). (b,c) MITF rescues DHLA and LA-inhibited tyrosinase activity. B16 cells
were transfected with either MITF or tyrosinase promoter luciferase reporter constructs and with either vector (pEBB) or MITF expression plasmid
(pEBB.bMi). Cell lysates were prepared following 24 h incubation with LA or DHLA. MITF overexpression rescues the tyrosinase promoter activity
inhibited by LA or DHLA (b), but has no e¡ect on MITF transcription (c). (d) Modulation of endogenous MITF mRNA levels. NHEM were treated with
DHLA (350 mM), LA (350 mM), and resveratrol (20 mg per ml) for 1 or 2 d, and with forskolin (100 mM) or TCM-1 (0.1 mg per ml) for 2 h, 1 d, or 2 d. Total
RNA (20 mg) was analyzed by northern blots, probed for MITF expression. The relative intensity of the MITF mRNA band is expressed as percent of
MITF signal intensity relative to untreated control, normalized to the 28S rRNA ethidium bromide stain. (e) Modulation of endogenous MITF and tyr-
osinase protein levels. Protein extracts from B16 cells treated with DHLA (350 mM), LA (350 mM), and forskolin (100 mM) for indicated times, were western
blotted and probed with anti-Mi antibodies followed by anti-tubulin and with aPEP-7 (anti-tyrosinase) antibodies.
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(data not shown). These data suggest that DHLA and TCM-1
may possibly target transcription factors/elements, which may
function cooperatively with the CRE binding protein(s) to
transactivate the MITF promoter.
Melanogenic gene expression is a¡ected by MITF
modulation As MITF regulates tyrosinase and Tryp1
expression (Yasumoto et al, 1994; Bentley et al, 1994; Hemesath
et al, 1994) we studied the e¡ect of DHLA, LA, and resveratrol
on the expression levels of these genes. B16 and melan-a cells
were transfected with the human MITF, tyrosinase, or Tryp1
promoter-luciferase reporter constructs. Following transfection,
cells were treated with forskolin, DHLA, or their combination,
and their relative luciferase activities were measured. As shown
in Fig 3(a), incubation with forskolin for 7 h increased both
MITF and tyrosinase promoter activities, but had no e¡ect, at
that time point, on Tryp1 promoter-driven transcription. DHLA
treatment signi¢cantly reduced the activity of all three
promoters, relative to their baseline transcription levels.
Moreover, DHLA was able to inhibit the forskolin-induced
expression of MITF and tyrosinase (Fig 3a). Similar inhibitory
activities were also observed using LA and resveratrol (not
shown).
To decipher whether the inhibitory e¡ect of DHLA and
LA on the tyrosinase promoter was mediated by the
downregulation of endogenous MITF gene expression, a rescue
study with overexpressed MITF was performed. A MITF
expression plasmid (pEBB.MITF) was cotransfected with MITF
or tyrosinase-luciferase constructs, and luciferase activity was
measured in the presence of DHLA and LA. Cells transfected
with vector alone (pEBB) served as a control. In B16 cells, the
inhibition of tyrosinase promoter activity by LA and DHLA
was rescued by the overexpressed MITF (Fig 3b) and further
increased (150%) relative to untreated cells. As a control, the
cotransfected MITF promoter, which was inhibited by LA or
DHLA, was not rescued by the overexpressed MITF (Fig 3c).
A further decrease in the MITF promoter-luciferase activity
was documented. This is possibly due to a feedback mechanism,
as the overexpressed MITF protein competes with the
cotransfected MITF promoter construct for endogenous
transcription factors; however, this hypothesis needs to be
further studied. These results indicate that the overexpressed
MITF protein could activate the tyrosinase promoter, whereas
the endogenous MITF promoter is still inhibited by LA or
DHLA. These data support a model in which the inhibition of
tyrosinase promoter activity by LA and DHLA is mediated by
downregulation of MITF gene expression.
Northern blot analysis was performed to con¢rm the
modulatory e¡ect of these agents on the endogenous levels of
MITF gene expression. NHEM cells were treated with test
compounds for di¡erent times, based on the time course of their
e¡ect on MITF promoter-luciferase activity. No signi¢cant
changes in cell numbers were observed following these
treatments. In agreement with the promoter studies, treatment
with DHLA, LA, and resveratrol reduced endogenous MITF
mRNA levels by 35%, 35%, and 63%, respectively, relative to
untreated control (normalized to gel loading by image analysis;
Fig 3d). TCM-1 treatment enhanced endogenous MITF
expression in normal melanocytes in a time-dependent manner,
with a maximum at 2 h, and a complete return to basal level by 2
d (Fig 3d). Similar results were obtained using melan-a or B16
cells (not shown). These data indicate that the modulation of
MITF promoter activity, as demonstrated by the luciferase
studies, correlates with the modulation of the endogenous MITF
expression pattern.
We then further investigated the e¡ect of DHLA and LA on
MITF and tyrosinase protein expression levels. B16 cells, treated
with LA (350 mM), DHLA (350 mM), and forskolin (100 mM) for 6,
24, and 48 h, were lyzed for western blot analysis. Probing with
Mi-speci¢c monoclonal antibody demonstrated that total Mi
protein levels [including phosphorylated and nonphosphorylated
melanocyte-speci¢c microphthalmia (M-Mi) bands] were
signi¢cantly reduced at 24 h post-treatment and returned to
almost basal levels at 48 h post-treatment (Fig 3e). Unlike
forskolin, LA and DHLA treatments did not produce an obvious
mobility shift of Mi (due to phosphorylation on serine 73) at
the time points tested (Hemesath et al, 1998). The ratio of
phosphorylated to nonphosphorylated Mi was retained, whereas
the total protein levels were changed. It is possible that LA or
DHLA could a¡ect phosphorylation of Mi at earlier time points.
Interestingly, the e¡ects of LA and DHLA treatments on
tyrosinase protein levels were found to be more signi¢cant than
their e¡ects on Mi. As shown in Fig 3(e), tyrosinase levels were
una¡ected at 6 h, reduced signi¢cantly at 24 h and continued to
decrease at 48 h, relative to untreated control. Forskolin treatment
increased tyrosinase protein expression level at 24 h and reduced
to a level even lower than untreated control by 48 h.
DHLA, LA, and TCM-1 treatments a¡ect tyrosinase
activity To investigate further the e¡ect of MITF transcription
modulation on melanogenesis, we studied the e¡ect of LA,
DHLA, and TCM-1 on tyrosinase activity in B16 cells. B16
cells were treated with DHLA (400 mM), LA (400 mM), forskolin
(100 mM), and TCM-1 (0.1 mg per ml) for 48 h, cells were
trypsinized, and treated cells (7104) were used for tyrosinase
analysis. As shown in Fig 4(a), DHLA (400 mM) and LA (400
mM) treatments reduced tyrosinase activity by 41.9% and 35.5,
whereas forskolin and TCM-1 increased tyrosinase activity by
17.0% and 132%, respectively. These data indicate that MITF
transcription modulators can regulate tyrosinase activity. Anti-
oxidants are also expected to inhibit directly tyrosinase
enzymatic activity. Therefore, untreated B16 cells were lyzed,
and aliquots of lysates were incubated with DOPA in the
presence or absence of DHLA, to measure directly the e¡ect of
DHLA on tyrosinase enzymatic activity. In parallel, B16 cells
were treated with DHLA in culture to measure the combined
e¡ect of DHLA on MITF transcription and directly on
tyrosinase enzymatic activity. As shown in Fig 4(b), the
enzymatic activity of tyrosinase was indeed inhibited by DHLA.
Treatment of the cells in culture with DHLA, however, further
decreased tyrosinase activity demonstrating a combined e¡ect on
MITF/tyrosinase gene expressions and on tyrosinase enzymatic
activity during melanogenesis.
Tyrosinase activity was also analyzed in treated NHEM cells in
situ by DOPA staining. As shown in Fig 4(c^k), forskolin and
TCM-1 treatments increased tyrosinase activity (Fig 4d,e relative
to untreated control c), whereas DHLA, LA, or resveratrol
signi¢cantly reduced tyrosinase activity in situ (Fig 4f^h). The
loss of DOPA staining following DHLA, LA, and resveratrol
treatments for 48 h correlates well with the greatest reduction of
tyrosinase protein expression level at this time point (see Fig 3e).
The tyrosinase activity induced by either TCM-1 or forskolin was
inhibited by DHLA (Fig 4i and Fig 4j, respectively) and LA
(Fig 4k, forskolin plus LA), further con¢rming the ability of
these agents to modulate pigmentation.
DHLA, LA, and resveratrol reduce skin pigmentation In
order to demonstrate the e¡ect of MITF modulating agents in
vivo, dark-skinned Yucatan swine were topically treated with
LA, DHLA, and resveratrol (1%) or with vehicle alone twice a
day, 5 d per wk, for 8 wk. These treatments (with the exception
of the vehicle alone) resulted in visible skin lightening (e.g.,
DHLA, Fig 5a) with no signs of irritation or other undesired
e¡ects. Histologic analysis using F&M staining demonstrates
reduced pigment deposition at the treated sites (DHLA, Fig 5c)
relative to the untreated control (Fig 5b). Image analysis of F&M-
stained sections quanti¢es this e¡ect (Fig 5d), further supporting
the notion that negative modulators of MITF could be used as
skin lightening agents.
DHLA, LA, and resveratrol inhibit UVB-induced
tanning DHLA was shown to inhibit UVB-induced MITF
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Figure 4. DHLA, LA, andTCM-1 treatments af-
fect tyrosinase activity. (a) Tyrosinase activity ana-
lysis of B16 cells, treated with test compounds. B16
cells treated for 24 h with forskolin (100 mM), DHLA
(400 mM), LA (400 mM), and TCM-1 (0.1 mg per ml)
were lyzed and incubated with 100 ml of 0.1% DOPA
for 3 h. Tyrosinase activity was determined by mea-
suring absorbance at 490 nm. Data expressed as per-
cent change of the tyrosinase activity relative to
untreated control (mean7SEM). (b) Analysis of tyr-
osinase enzymatic activity in DHLA-treated cells and
lysates. B16 cells were either lyzed and then incubated
with DHLA and DOPA for 3 h (open bars) or treated
with DHLA in culture and then lyzed (hatched bars).
The e¡ect of DHLA on the enzymatic activity of tyr-
osinase in the lysate (open bars) was compared with
the e¡ect of DHLA on live cells (hatched bars). (c^k)
Modulation of tyrosinase activity in situ. NHEM
were treated with 100 mM forskolin (d), 0.1 mg TCM-
1 per ml (e), 350 mM DHLA (f), 350 mM LA (g), 20 mg
resveratrol per ml (h), forskolin and DHLA (i), for-
skolin and LA (j), and TCM-1 and DHLA (k). Un-
treated control is shown in (c). Cells were DOPA
stained following 48 h incubation with test agents.
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promoter activity (Fig 2c). Therefore, the ability of DHLA to
inhibit UVB-induced pigmentation by MITF transcription
modulation was also tested in vivo. Light-skinned Yucatan swine
were UVB irradiated as described in Materials and Methods, to
create a visible tanning response. UVB-irradiated sites were
treated with test compounds or controls once daily, for 10 d,
either immediately after UVB exposure or on non-UVB
exposure days, and the level of tanning was monitored visually
and histologically. Treatment with UVB alone or with UVB
and vehicle induced visible darkening, which was con¢rmed
histologically using F&M staining (compare Fig 6b, UVB and
vehicle treatment, to the untreated skin shown in Fig 6a).
Treatments with DHLA, LA, and resveratrol (Fig 6c^e,
respectively), reduced the UVB-induced pigment deposition.
Image analysis of F&M-stained sections quanti¢es this e¡ect
(Fig 6f), further con¢rming that modulation of MITF
transcription by these agents could reduce UVB-induced
tanning.
DISCUSSION
Solar irradiation is a major source of environmental damage to
skin, and UV-induced skin pigmentation has been widely recog-
nized as a defense mechanism against such damage (Ortonne,
1990; Kollias et al, 1991; Gilchrest, 1998; Sturm, 1998; Chakraborty
et al, 1999; Gilchrest and Eller, 1999). The transcription factor
MITF plays a key role in pigmentation, but has not been asso-
ciated with the e¡ect of UVB on pigment production. To better
understand the molecular mechanism of UVB-induced pigmen-
tation, we examined the e¡ect of UVB irradiation on MITF gene
expression. This study demonstrates that UVB can induce MITF
promoter activity in vitro in a time- and concentration-dependent
manner. Furthermore, the induction of MITF promoter activity
by UVB was not identical to that of forskolin and was delayed
relative to that of forskolin-induced MITF transcription. It has
been shown previously that UVB-mediated events could be mi-
micked or enhanced by MSH (Im et al, 1998), and that expo-
sure to sunlight results in increased levels of circulating MSH
and adrenocorticotropic hormone in both horse and human
(Bolognia et al, 1994; Im et al, 1998; Suzuki et al, 1999). Therefore,
we hypothesized that MITF promoter activity may be indirectly
mediated by UVB and that the activation step may involve
the release of MSH and/or adrenocorticotropic hormone. The
Figure 5. DHLA reduces skin pigmentation
in vivo. Dark-skinned Yucatan swine were topi-
cally treated with 1% LA, 1% resveratrol per ml,
1% DHLA or vehicle, twice a day, 5 d per wk, for
8 wk. (a) Picture of a treated site, taken at 8 wk of
treatment, demonstrating DHLA-induced skin
lightening. (b,c) F&M staining of histologic sec-
tions of untreated (b) and DHLA-treated (c) sites.
(d) Relative pigmentation (melanin area divided
by total epidermis area), as analyzed using com-
puterized imaging.
Figure 6. Prevention of UVB-induced tanning. Light-skinned Yuca-
tan swine were UVB treated with 1 mean erythema dose to create visible
tanning as described in Materials and Methods, with or without daily treat-
ment of test material. Tanning was observed in UVB alone and in UVB
and vehicle-treated sites, and was reduced or prevented with LA, DHLA,
and resveratrol treatments. F&M staining of histologic sections con¢rm
this observation: (a) untreated control; (b) UVB plus vehicle; (c) UVB plus
LA (1%); (d) UVB plus DHLA (1%); (e) UVB plus resveratrol (1%).
Relative pigmentation (melanin area divided by total epidermis area), as
analyzed using computerized imaging, is shown in ( f ).
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delayed activation of MITF by UVB (relative to that of 3^4 h by
forskolin) is in agreement with the time frame required for the
processing and release of MSH and adrenocorticotropic hormone
(Bolognia et al, 1994; Im et al, 1998;reviewed in Suzuki et al, 1999).
In turn, released MSH and/or adrenocorticotropic hormone could
transactivate the MITF promoter through the CRE and/or other
transcription factors (Busca and Ballotti, 2000). Indeed, MSHwas
shown to transactivate the MITF promoter activity, although
with relative lower activity compared with forskolin and to in-
crease MITF protein levels in B16 cells as described by Price et al
(Price et al, 1998b). MITF is regulated by two signaling pathways,
the MSH and c-Kit pathways (reviewed in Fisher, 2000;Tachibana,
2000). As the c-Kit and the MSH signal transduction pathways
have di¡erent kinetics (minutes vs hours) (Price et al, 1998a), we
suggest that UVB exerts its e¡ect on MITF promoter via the
MSH, and not via the c-Kit pathway.
UV irradiation is known to induce the production of reactive
oxygen species in human skin, resulting in oxidative stress and
damage (Dalle and Pathak, 1992; Tyrrell, 1995; de Gruijl, 2000).
Anti-oxidants have been widely used in skin-care products to
provide photoprotection (Hamanaka et al, 1990; Darr et al, 1996;
Lee andYoun, 1998; Firkle et al, 2000). Of the many anti-oxidants
tested in this study, however, only LA, DHLA, and resveratrol
were found to a¡ect MITF promoter activity and reduce endo-
genous MITF mRNA and protein levels.Vitamin C, ca¡eic acid,
pycnogenol, glutathione, and concentrated green tea polyphenols,
which are known strong anti-oxidants, had no e¡ect on
MITF promoter activity, at either baseline or following UVB
or forskolin induction. These ¢nding suggests that the anti-
oxidant activity per se is not involved in the regulation of
MITF transcription.
DHLA and LA are strong anti-oxidants, known for their abil-
ity to prevent UV-induced photo-oxidative damage (Packer et al,
1995; Saliou et al, 1999; Alvarez and Boveris, 2000). LA plays an
important part in mitochondrial dehydrogenase actions. Its re-
duced form, DHLA, exhibits a slightly higher anti-oxidant activ-
ity than LA, by reacting with superoxide and hydroxyl radicals
(Packer et al, 1995). resveratrol is a polyphenolic compound found
in edible plants such as grapes and peanuts. Resveratrol contri-
butes to the anti-oxidant potential of red wine by acting as a re-
active oxygen species scavenger and is believed to prevent
cardiovascular diseases, and to have anti-in£ammatory and che-
mopreventive activities (Fremont, 2000). Interestingly, resveratrol
has no chemical structure similarity to DHLA and LA, whereas it
also exhibited strong inhibition of MITF and tyrosinase promo-
ter activities in our studies. TCM-1, an extract of the plantAstra-
gulus membraneus, has been used orally as traditional Chinese
medicine for many years. TCM-1 is believed to enhance immu-
nity, to strengthen the body, to have a diuretic e¡ect, and to a¡ect
cardiovascular function by reducing blood viscosity (Terry, 1996).
To our surprise,TCM-1 induced MITF expression and tyrosinase
activity in normal human melanocytes to the same or even high-
er extent than forskolin. A combination of TCM-1 and forskolin
resulted in less than additive stimulation, suggesting either a
saturation of transcription inducibility, or a pathway shared
by these agents. Furthermore, the kinetics of MITF induction
byTCM-1was similar to that of forskolin, and LA, DHLA, and
resveratrol inhibited both forskolin- and TCM-1 induced
pigmentation.
Forskolin is known to elevate cAMP levels (Seamon and Daly,
1981, 1986; Seamon et al, 1981), and the melanocyte-speci¢c MITF
promoter contains a CRE (Fuse et al, 1996; Bertolotto et al, 1998;
Price et al, 1998b). Forskolin-induced MITF and tyrosinase ex-
pression is melanocyte speci¢c (Price et al, 1998b), providing an
example of tissue restricted CRE responsiveness. The mechanistic
basis for this restriction is not yet understood.Whereas forskolin
upregulates cAMP levels in melanocytes, however, no changes in
cAMP production were identi¢ed following either TCM-1,
UVB (not shown), or DHLA treatment. Moreover, DHLA was
able to inhibit completely the forskolin-induced MITF promoter
activity without decreasing the cAMP levels induced by forsko-
lin. Our preliminary data demonstrate that a mutated MITF
CRE sequence, known to inhibit MITF promoter responsiveness
to forskolin (Bertolotto et al, 1998; Price et al, 1998b), is not re-
sponsive to TCM-1 induction. These data suggest that DHLA
and TCM-1 possibly target other transcription factor elements
on the MITF promoter that may function cooperatively with
CRE binding protein(s) to transactivate MITF. Several transcrip-
tion factors (e.g., Sox 10, Pax 3, and a-catenin/TCF-LEF-1) have
been shown to regulate the MITF promoter (Watanabe et al, 1998;
Lee et al, 2000; Potterf et al, 2000;Takeda et al, 2000;Verastegui et
al, 2000b). These factors might potentially cooperate with CRE
binding protein(s) to enable the MITF promoter activity only in
melanocytes. The mutated CRE therefore might not only lose
cAMP responsiveness, but could also a¡ect interactions with
other transcription factors involved in MITF activation. DHLA,
LA, and resveratrol could inhibit the MITF promoter activity by
a mechanism that may interfere with these interactions. Alterna-
tively, it is possible that cAMP would re-localize within the mel-
anocytes upon DHLA andTCM-1 treatments without changes in
total cAMP concentration. Whereas such a mechanism has not
yet been documented, it could not be ruled out as tools are not
available for such an analysis. More interestingly, recent studies
demonstrate that MITF interacts with LEF-1, a mediator of Wnt
signaling, and activates its own gene expression (Takeda et al,
2000; Shibahara et al, 2001; Saito et al, 2002), which could be af-
fected by our test agents (Shibahara et al, 2001; Saito et al, 2002).
In addition to the inhibition of MITF promoter activity,
DHLA, LA, and resveratrol a¡ected tyrosinase and Tyrp1 promo-
ter activities and tyrosinase activity. The inhibitory e¡ect of these
agents on tyrosinase promoter activity could be rescued by MITF
overexpression, further supporting the notion that these agents
a¡ect MITF transcription. Furthermore, northern and western
blot analyses con¢rmed the modulation of MITF gene expression
by DHLA and LA. The inhibition of tyrosinase protein expres-
sion levels by LA and DHLA is greater than the inhibition of
MITF protein levels (especially at 24 h post-treatment). As MITF
binds to and activates tyrosinase, one would expect to see the de-
layed change of tyrosinase gene expression relative to that of
MITF followed MITF modulators. Indeed, the inhibition of tyr-
osinase expression was found to be delayed relative to that of
MITF by DHLA and LA in this study (Fig 3e), and the induction
of tyrosinase expression was also delayed in the B16 cells treated
with a-MSH (Verastegui et al, 2000a). Based on the di¡erential
kinetic regulations of MITF and tyrosinase, it is possible that the
profound e¡ect of these treatments on MITF protein expression
may be seen between 6 and 24 h. This also suggests that these
agents might a¡ect other transcription factors (e.g., Usf-1), which
may directly a¡ect tyrosinase expression. Usf-1 is a transcription
factor involved in UV-induced tyrosinase expression (Galibert
et al, 2001). Further studies are required to better understand the
role of Usf-1 and of other MITF transcription factors in the
DHLA and LA induced depigmentation. Finally, DHLA, LA,
and resveratrol inhibited both basal and forskolin- or TCM-1-in-
duced tyrosinase activities in situ without further a¡ecting cell
density (Fig 4c^k). These agents also inhibited tyrosinase enzy-
matic activity in a test-tube assay, but to a lower level (even
though their e¡ective concentration in culture was much lower).
This indicates a dual mechanism a¡ected by these agents, of both
decreased gene expression and inhibited enzymatic activity in live
cells.
DHLA was found to depigment dark-skinned swine (Fig 5)
and to prevent UVB-induced tanning in vivo. This suggests that
modulation of MITF transcription by exogenous agents could be
used to modulate skin pigmentation. Due to the lack of swine
molecular tools, however, we were unable to provide direct
in vivo evidence for the modulation of MITF expression. Topical
application of TCM-1 did not result in a noticeable increase in
skin color using the same animal model (not shown). This might
be due to ine¡ective or insu⁄cient delivery of the active agents
within the TCM-1 extract to the basal layer of the epidermis. Al-
ternatively, this might be due to the intrinsically limited capacity
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of light-skinned swine to respond to pigmentary stimulation, as
forskolin (24 mM) did not induce visible darkening in this animal
model.
We show that UVB irradiation results in increased MITF tran-
scription in vitro. Agents that reduce MITF transcription in vitro
are shown to depigment swine skin, and to prevent UVB-in-
duced tanning. These agents are shown to inhibit tyrosinase ex-
pression and activity via their MITF transcription modulating
e¡ect. This study suggests that such agents could be used to alter
skin pigmentation. The precise mechanism of modulation of
MITF promoter activity by these agents should be further
investigated.
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